{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:57Z","timestamp":1789473837127,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40291-026-00843-8","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:35:05Z","timestamp":1774463705000},"page":"539-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Etuvetidigene Autotemcel: First Approval"],"prefix":"10.1007","volume":"30","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"843_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/TACG.S58444","volume":"7","author":"D Buchbinder","year":"2014","unstructured":"Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott\u2013Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55\u201366.","journal-title":"Appl Clin Genet"},{"key":"843_CR2","unstructured":"Fondazione Telethon ETS. WASKYRA (etuvetidigene autotemcel) suspension, for intravenous use: US prescribing information. 2025. https:\/\/www.fda.gov\/media\/190096\/download?attachment. Accessed 23 Feb 2026."},{"key":"843_CR3","unstructured":"Orchard Therapeutics. Orchard Therapeutics announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation granted for OTL-103 for the treatment of Wiskott\u2013Aldrich syndrome [media release]. 29 Jul 2019. https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-announces-fda-regenerative-medicine."},{"key":"843_CR4","unstructured":"US Food & Drug Administration. FDA approves first gene therapy treatment for Wiskott\u2013Aldrich Syndrome [media release]. 9 Dec 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome."},{"key":"843_CR5","unstructured":"Fondazione Telethon. Fondazione Telethon announces FDA approval of Waskyra\u2122 (etuvetidigene autotemcel), a gene therapy for the treatment of Wiskott\u2013Aldrich Syndrome [media release]. 10 Dec 2025. https:\/\/www.fondazionetelethon.it\/en\/stories-and-news\/news\/from-telethon-foundation\/fondazione-telethon-announces-fda-approval-of-waskyra-etuvetidigene-autotemcel-a-gene-therapy-for-the-treatment-of-wiskott-aldrich-syndrome\/"},{"key":"843_CR6","unstructured":"Fondazione Telethon. Fondazione Telethon receives european marketing authorisation for Waskyra\u2122 (etuvetidigene autotemcel), a gene therapy for the treatment of Wiskott\u2013Aldrich syndrome [media release]. 16 Jan 2026. https:\/\/www.fondazionetelethon.it\/en\/stories-and-news\/news\/from-telethon-foundation\/fondazione-telethon-receives-european-marketing-authorisation-for-waskyra-etuvetidigene-autotemcel-a-gene-therapy-for-the-treatment-of-wiskott-aldrich-syndrome\/."},{"key":"843_CR7","unstructured":"European Medicines Agency. Waskyra (etuvetidigene autotemcel) 2\u201310 \u00d7 106 cells\/mL dispersion for infusion: EU summary of product characteristics. 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/waskyra. Accessed 23 Feb 2026."},{"key":"843_CR8","unstructured":"GSK. GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases [media release]. 17 Oct 2010. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-fondazione-telethon-and-fondazione-san-raffaele-to-collaborate-on-gene-therapy-for-rare-diseases\/."},{"key":"843_CR9","unstructured":"GlaxoSmithKline, Orchard Therapeutics. GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics [media release]. 12 Apr 2018. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-signs-strategic-agreement-to-transfer-rare-disease-gene-therapy-portfolio-to-orchard-therapeutics\/."},{"key":"843_CR10","unstructured":"Orchard Therapeutics. Orchard Therapeutics announces global license agreements for stable cell line technology from GSK [media release]. 15 Jul 2020. https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-announces-global-license-agreements-stable."},{"key":"843_CR11","unstructured":"Orchard Therapeutics. Orchard Therapeutics extends runway into 2024, focusing HSC gene therapy platform exclusively on severe neurometabolic diseases and research platform [media release]. 30 Mar 2022. https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-extends-runway-2024-focusing-hsc-gene."},{"key":"843_CR12","unstructured":"Orphan Therapeutics. Fondazione Telethon and Orphan Therapeutics Accelerator sign Memorandum of Understanding to pioneer non-profit commercial access model for ultra-rare disease gene therapy in the US [media release]. 15 Dec 2025. https:\/\/www.orphantherapies.com\/news\/fondazione-telethon-and-orphan-therapeutics-accelerator-sign-memorandum-of-understanding-to-pioneer-non-profit-commercial-access-model-for-ultra-rare-disease-gene-therapy-in-the-us."},{"key":"843_CR13","doi-asserted-by":"publisher","unstructured":"Ferrua F, Cenciarelli S, Giannelli S, et al. Etuvetidigene autotemcel for the treatment of Wiskott\u2013Aldrich Syndrome. medRxiv. 2025. https:\/\/doi.org\/10.64898\/2025.11.25.25340584.","DOI":"10.64898\/2025.11.25.25340584"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00843-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:47:03Z","timestamp":1778651223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00843-8","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}